Limited coverage criteria – risankizumab for plaque psoriasis

Last updated on March 21, 2025

Special Authority requests can now be submitted online. It's simple and quick!

Learn more or log in

Return to Special Authority drug list

Generic name	risankizumab
Strength & form	75 mg/ 0.83 mL pre-filled syringe (subcutaneous injection) 150 mg/mL pre-filled pen (subcutaneous injection)

Generic name

risankizumab

Strength & form

75 mg/ 0.83 mL pre-filled syringe (subcutaneous injection)

150 mg/mL pre-filled pen (subcutaneous injection)

Special Authority criteria	Approval period
For the treatment of moderate to severe plaque psoriasis, according to established criteria described in HLTH 5380 – Biologics for Moderate to Severe Plaque Psoriasis (PDF, 781KB), when a Special Authority request is submitted by a dermatologist	Initial: 16 weeks Renewal: 1 year

Special Authority criteria

Approval period

For the treatment of moderate to severe plaque psoriasis, according to established criteria described in HLTH 5380 – Biologics for Moderate to Severe Plaque Psoriasis (PDF, 781KB), when a Special Authority request is submitted by a dermatologist

Initial: 16 weeks

Renewal: 1 year

Practitioner exemptions

None

Special notes

PharmaCare coverage of risankizumab is limited to 150 mg every 12 weeks at maintenance dosing. 150 mg loading doses are covered at weeks 0, 4 and 16

Special Authority request form(s)

Did you find what you were looking for?

The B.C. Public Service acknowledges the territories of First Nations around B.C. and is grateful to carry out our work on these lands. We acknowledge the rights, interests, priorities, and concerns of all Indigenous Peoples - First Nations, Métis, and Inuit - respecting and acknowledging their distinct cultures, histories, rights, laws, and governments.

More topics